Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Long-COVID


The GNC-501 study, entitled “Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric Symptoms in Post-COVID-19 or Post-Acute Sequelae of COVID-19 (PASC) Syndrome”, will enroll 200 patients from Swiss and EU study centres suffering from severe neuropsychiatric syndromes following COVID infection. The biomarker-based study will enrol only patients who are also tested positive for the pathogenic protein W-ENV, with the objective to reduce their invalidating conditions.

Current active sites:

Geneva, Switzerland: Hôpital Universitaire de Genève - https://recherche.hug.ch/etudes/temelimab